Evidence suggests that the stress hormones glucocorticoids (GCs) can cause cognitive deficits and neurodegeneration. Previous studies have found GCs facilitate physiological synapse weakening, termed long-term depression (LTD), though the precise mechanisms underlying this are poorly understood. Here we show that GCs activate glycogen synthase kinase-3 (GSK-3), a kinase crucial to synapse weakening signals. Critically, this ultimately leads to phosphorylation of the microtubule associated protein tau, specifically at the serine 396 residue, and this is a causal factor in the GC-mediated impairment of synaptic function. These findings reveal the link between GCs and synapse weakening signals, and the potential for stress-induced priming of neurodegeneration. This could have important implications for our understanding of how stress can lead to neurodegenerative disease.
Introduction
Repeated and chronic stress can cause acceleration of brain ageing, memory deficits and various mental illnesses [1, 2] . Rising levels of the stress hormone cortisol are strongly correlated with temporal lobe atrophy and cognitive deficits during ageing in humans [2] . These effects are prevalent in patients with hypercortisolism [3, 4] and can even be mirrored in otherwise healthy individuals by repeated exposure to environmental stressors such as jet lag [5] . It has been reported that prolonged secretion of glucocorticoids (GCs) during chronic stress, or exogenous application of GCs, disrupts memory performance in both humans [6, 7] and rodents [8] [9] [10] . Understanding the precise mechanisms underpinning how elevated-GCs cause both cognitive deficits and structural atrophy in the brain remains a major scientific challenge with numerous translational implications.
Several rodent studies have demonstrated that stress and GCs inhibit long-term potentiation (LTP) but enhance long-term depression (LTD) [11, 12] . Given the postulated role for these synaptic phenomena in learning and memory [13] , it is likely that their dysregulation is central to the cognitive impairments induced by GCs. Although the activation of glucocorticoid receptors (GRs) triggers a wide variety of intracellular signals [14] [15] [16] , the synaptic signalling pathways that underlie aberrant synapse weakening by GCs remain to be elucidated.
Based on the aforementioned findings, one possibility is that GCs regulate the direction of plasticity and/or the fate of synapses via modulation of certain signalling pathways involved in LTD, or synapse weakening. A key molecule linking synapse weakening and disruption of LTP expression is glycogen synthase kinase-3 (GSK-3) [17] . Our previous studies also implicate caspase-3-induced cleavage of Akt1 as a critical factor for the expression of physiological LTD [18] , and suggest that it acts as an upstream regulator of GSK-3 to enhance LTD in amyloid-beta (A␤)-mediated pathophysiological conditions [19] . Furthermore, GSK-3 orchestrates this synapse weakening mechanism through regulation of tau phosphorylation (pTau) [20, 21] . Given the key role of aberrant pTau in the pathophysiology of Alzheimer's disease and stress-mediated neurodegeneration [22] [23] [24] , we hypothesise that GSK-3-mediated signalling pathways leading to pTau could be a synapse weakening mechanism common to these diseased states.
Here we provide evidence that GCs activate a synapse weakening signal pathway centred around the cleavage of Akt1 by caspase-3 and subsequent activation of GSK-3, which causes aberrant pTau and abolishes LTP expression in the rat hippocampus. We identify a single pTau residue (Ser396) as a critical downstream signal in this mechanism, resulting in GC-mediated aberrant synaptic weakening. These findings could provide further translation to our understanding of how GCs prime progressive neurodegeneration through aberrant functional plasticity in the hippocampus.
Materials and methods

Animals
Experiments involving animals were conducted in accordance with the UK Animals Scientific Procedures Act, 1986 and associated guidelines. All experimental protocols were approved by the University of Bristol Animal Welfare & Ethical Review Body. Male Wistar rats (Charles River, UK) were used to prepare organotypic (7-day-old rats) and acute hippocampal slices (4-to 5-week-old rats). Rats were housed four or five per cage, and were allowed access to water and food ad libitum. The cages were maintained at a constant temperature (23 ± 1 • C) and relative humidity (60 ± 10%) under a 14/10 h light-dark cycle (lights on from 8:00 A.M.).
Electrophysiology
Acute hippocampal slice field recording
Animals were sacrificed from 9:00-10:00 A.M. by cervical dislocation. Brains were quickly removed into ice-cold artificial cerebrospinal fluid (ACSF; 124 mM NaCl, 3 mM KCl, 26 mM NaHCO 3 , 1.25 mM NaH 2 PO 4 , 2 mM CaCl 2 , 1 mM MgSO 4 , 10 mM D-glucose, carbogenated with 95% O 2 /5% CO 2 ). Hemispheres were separated with a midsagittal cut and hippocampi were micro-dissected from each intact hemisphere. Transverse hippocampal slices (400 m) were cut using a Mcllwain tissue chopper (Mickle Laboratory Engineering) and allowed to recover in a submersion-type bath filled with ACSF for at least 60 min. Before recording, hippocampal slices were incubated in ACSF with pharmacological compounds at room temperature. Evoked field excitatory postsynaptic potentials (fEPSPs) were recorded in the CA1 region using glass electrodes containing NaCl (3 M). Stimulating electrodes placed in the subiculum and CA2 region (Schaffer collateral pathway). Stimuli were delivered alternately to the two electrodes at a baseline rate of 0.066 Hz. Stimulus intensity was set at 30-40% of saturating intensity. After 30 min of stable baseline, high-frequency stimulation (2 × 100 pulses; 100 Hz, 30 s interval) was used for the LTP induction protocol. LTP was gauged as the change of fEPSP slope relative to the preconditioning baseline. Both control and experimental recordings were collected using slices prepared from the same animal. Analysis of control LTP data across all field recording experiments showed no significant difference between mean postconditioning fEPSPs in slices prepared from different rats (one-way ANOVA, F(4,33) = 2.147, p = 0.097). Data were captured and analysed using LTP114j software. Data are expressed relative to a normalized baseline. For analyses, the baseline was defined as 5 points before tetanic stimulation and the post-conditioning time was set at 75-80 min following recording commencement. The difference between baseline and post-conditioning time-points was expressed as a percentage of baseline ±SEM, and was used to make comparisons between treatment groups.
Hippocampal slice culture and biolistic transfection
Organotypic slices were cultured based upon a method previously described by Stoppini et al. [25] . Briefly, rats were decapitated, and their brains rapidly removed and placed into icecold dissecting medium containing: 238 mM sucrose, 2.5 mM KCl, 26 mM NaHCO 3 , 1 mM NaH2PO4, 5 mM MgCl 2 , 11 mM d-glucose, and 1 mM CaCl 2 . Hippocampi were extracted, and transverse hippocampal slices (350 m thickness) were cut and placed upon sterile, semi-porous membranes. These were stored and maintained at the interface between air and culture medium (containing: 78.8% Mimimum Essential Medium, 20% heat-inactivated horse serum, 30 mM HEPES, 26 mM d-glucose, 5.8 mM NaHCO 3 , 2 mM CaCl 2 , 2 mM MgSO 4 , 70 M ascorbic acid, 1 g/ml insulin, pH 7.3 and 320-330 mOsm/kg) inside a humidified incubator at 35 • C with a 5% CO 2 -enriched atmosphere. Culture medium was refreshed every 2 days, and slices were used for whole-cell recording at 6-8 days in vitro (DIV).
DNA-coated microcarriers for biolistic transfection of organotypic hippocampal slices were prepared based on previously described methods [26] . At DIV 3-5, neurons were transfected with plasmids expressing shRNA against rat tau protein (OriGene Technologies). A mixture of four different tau shRNA constructs (1:1:1:1, in pGFP-V-RS vector) was used for tau silencing. Phosphorylationnull (serine residues mutated to alanine) human tau constructs of the AT8 [S199, S202, threonine 205 (T205)] and PHF-1 (S396, S404) epitopes, in pCI-neo vectors, were kindly provided by Dr. A. Takashima (Department of Aging Neurobiology, National Center for Geriatrics and Gerontology, Obu, Japan). Individual mutations to the PHF-1 epitope (residues S396 or S404) were generated by sitedirected mutagenesis (Agilent Technologies) of 2N4R human tau. Wild-type and triple mutant Akt1 (D108A/D119A/D462N) were generated as previously described [18] .
Whole-cell patch clamp recording
For whole-cell recordings from cultured organotypic slices, the recording chamber was perfused with a buffer solution containing 119 mM NaCl, 2.5 mM KCl, 4 mM CaCl 2 , 4 mM MgCl 2 , 26 mM NaHCO 3 , 1 mM NaH 2 PO 4 , 11 mM glucose, 0.02 mM picrotoxin, and 0.01 mM 2-chloroadenosine. The buffer solution was maintained at 29-30 • C and saturated with 95% O 2 /5% CO 2 . Recording electrodes (5-6 M ) containing CsMeSO 4 filling solution (130 mM CsMeSO 4 , 8 mM NaCl, 4 mM Mg-ATP, 0.3 mM Na-GTP, 0.5 mM EGTA, 10 mM HEPES, and 6 mM QX-314, pH 7.2-7.3 and 270-290 mOsm/kg) were used to voltage clamp CA1 pyramidal neurons. EPSCs were recorded at a holding voltage of −70 mV, and only cells that had an initial Rs (series resistance) < 20 M that was maintained within 20% of that value from start to finish were included in final data analysis. To induce LTP, depolarization of the cell to 0 mV was paired with 200 pulses of 2 Hz stimulation to the Schaffer collateral input. Analysis of control LTP data across all whole cell patch recording experiments showed no variation in interleaved control LTP levels over time and in different slices (one-way ANOVA, F(4,11) = 1.775, p = 0.230). The change in peak amplitude of the EPSC, relative to baseline, was used to assess the effects of these stimulation protocols on synaptic efficacy. For analysis purposes, the baseline was defined as 5 points before 2 Hz stimulation and the post-conditioning time was set as the last 5 points at the 40-min time-point. The difference between baseline and post-conditioning time-points was expressed as a percentage of baseline ±SEM, and was used to make comparisons between treatment groups.
Western blotting and antibodies
Hippocampal slices were collected and homogenised in lysis buffer (1% SDS, 292 mM sucrose, 2.6 mM EDTA, 1:10 Protease Inhibitor Cocktail (Sigma Aldrich), 1:100 Phosphatase Inhibitor Cocktail 3 (Sigma Aldrich)). For immunoblotting, primary antibodies were used at the following dilutions: anti-phospho-GSK-3␤ Ser9 (rabbit polyclonal, Cell Signalling Technology, 1:500), anti-GSK-3␤ (H-76) (rabbit polyclonal, Santa Cruz Biotechnology, 1:500), anti-phospho-Akt1 Ser473 (rabbit polyclonal, Cell Signalling, 1:1000), anti-phosphoAkt1 Thr308 (rabbit polyclonal, Cell Signalling, 1:1000), anti-Akt1 (rabbit polyclonal, Cell Signalling, 1:1000), anti-PHF-1 (mouse monoclonal, kindly provided by Dr. P. Davies, 1:1000), antiphospho-Tau Ser396 (rabbit polyclonal, Life Technologies, 1:1000), anti-phospho-Tau Ser404 (rabbit polyclonal, Life Technologies, 1:1000), anti-phospho-PHF-tau pSer202 + Thr205 (AT8) (Mouse monoclonal, Thermo Scientific, 1:1000), anti-Tau 5 (mouse monoclonal, Life Technologies, 1:1000), anti-␤-Actin (mouse monoclonal, Abcam, 1:10,000).
Membranes were incubated in horseradish peroxidase-conjugated secondary antibodies at the following dilutions: anti-rabbit (goat polyclonal, Millipore, 1:5000), antimouse (goat polyclonal, Millipore, 1:5000), followed by imaging with the G:Box gel imaging system (Syngene) using the EZ-ECL detection system (Thermo Scientific Inc.). Optical densities of immunoreactive bands were measured using ImageJ software (NIH) and statistical analysis conducted with SigmaPlot (Systat Software, Inc., USA). Example blots were cropped around regions of interest for presentation in figures. For quantitative comparisons of treatment groups, optical densities for proteins of interest were normalized to loading-control protein levels and expressed relative to the average value from the control group.
Akt1 kinase assay
Akt1 activity was determined as described by the manufacturer's instructions (Cell Signalling), with minor modifications. Acute hippocampal slices were washed with TBS and homogenised in IP buffer (25 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 1 mM PMSF, 1 mM Na-Orthavanadate, 1× phosphatase inhibitors and 1× Protease inhibitors). Lysates were centrifuged at 15,000g for 15 min at 4 • C and the supernatant transferred to fresh tubes. Immunoprecipitation of Akt1 was performed using 500 g of lysate and incubated with 2 g of Akt1 Ser473 antibody overnight at 4 • C. Subsequently, 30 l of washed Protein G agarose slurry was added and incubated at 4 • C for 45 min with over-end mixing. The beads were washed twice in IP buffer, followed by two washes in NEB kinase buffer. The immobilised precipitated Akt1 was incubated in 40 l kinase buffer containing 200 M ATP and 1 g of GSK3␤ fusion protein at 30 • C for 30 min. The reaction was stopped by addition of 20 l of 3× sample buffer. The samples were vortexed and centrifuged prior to heating and protein separation by SDS-PAGE.
Statistical analysis
Where practically possible, experiments were performed blind to experimental condition. Results are presented as the mean ± standard error of the mean (SEM). Results were analysed using unpaired t-test for two independent groups or by one-way ANOVAs with post-hoc Holm-Sidak analysis for multiple groups, as indicated in the results text and figure legends. p < 0.05 was considered statistically significant. N numbers represent samples from independent animals unless otherwise specified.
Results
GCs activate a synapse weakening pathway to inhibit LTP
In acutely prepared dorsal hippocampal slices, corticosterone (CORT; 1 M) application for 2 h (Ctrl: 146.12 ± 2.9%; CORT: 114.33 ± 5.6%, unpaired t-test t(13) = 5.2, p < 0.001, Fig. 1a ), or application of the synthetic glucocorticoid dexamethasone (DEX; 200 nM, 2 h, Ctrl: 164.35 ± 4.5%; DEX: 133.92 ± 3.9%, unpaired ttest, t(12) = 4.9, p < 0.001, Fig. 1b) , both inhibited LTP induction when compared to untreated slices. No effects of CORT treatment on basal properties of synaptic transmission were observed ( Supplementary Fig. S1 ). Based on previous studies [18] [19] [20] [21] , we hypothesised that GCs activate a caspase-3-Akt1-GSK-3 signalling (CAG) cascade that induces aberrant expression of LTD and inhibits LTP. We therefore tested whether GC exposure impairs LTP via activation of this CAG cascade. Co-application of the GSK-3 inhibitor CT-99021 (1 M) prevented the LTP impairment that was induced by CORT treatment alone (CORT: 114 ± 5.3%; CORT + CT-99021: 142.9 ± 3.8%, unpaired t-test, t(10) = 3.1, p = 0.0114, Fig. 1c ), suggesting that GSK-3 activation is required for CORT-mediated inhibition of LTP. Fig. 1d) . Indeed, the activation of GSK-3 was robustly induced by CORT treatment and was prevented by pre-treatment (30 min) and co-application of Z-DEVD-FMK (one-way ANOVA, F(3,36) = 14.41, p < 0.001; Holm-Sidak post hoc test for CORT (56.7 ± 9.6%) vs CORT + Z-DEVD-FMK (89.1 ± 6.4%, p = 0.031), Fig. 1e ). Z-FA-FMK had no effect on the CORT-induced activation of GSK-3␤ (CORT (56.7 ± 9.6%) vs CORT + Z-FA-FMK (58.8 ± 7.9%, p = 0.858, Fig. 1e) ) and neither Z-DEVD-FMK nor Z-FA-FMK altered the total expression level of GSK-3␤ (one-way ANOVA, F(3,39) = 0.09, p = 0.96, Fig. 1e) .
We also utilized a previously characterised XIAP Bir 1,2 protein, which inhibits caspase-3 and 7 activation [18] . XIAP Bir 1,2 was biolistically transfected into neurons of cultured hippocampal slices. In this cultured slice model, cells exposed to CORT treatment (200 nM, 24 h) exhibited impaired LTP when compared to untreated cells (untreated: 160.1 ± 14.0%; CORT: 93.7 ± 15.2%, unpaired t-test t(8) = 3.2, p = 0.012, Fig. 1f ). This effect was dependent upon the presence of the GR, such that CORT failed to block LTP in neurons transfected with GR shRNA when compared to untransfected cells (untransfected: 85.7 ± 12.5%; GR-shRNA transfected: 157.3 ± 24.9%, unpaired t-test t(8) = 2.6, p = 0.033, Fig. 1g ). CORT treatment did not inhibit LTP in XIAP Bir1,2 overexpressing cells when compared to untransfected cells (untransfected: 103.6 ± 20.8%; XIAP Bir1,2 transfected: 169.5 ± 20.2%, unpaired ttest t(11) = 2.3, p = 0.044, Fig. 1h with our hypothesis, these results suggest that CORT induces both GSK-3 and caspase activation.
GCs inhibit LTP via Akt1 regulation
Since the mitochondrial permeability transition pore (mPTP) is important for the activation of caspases [27] , we tested whether mPTP regulates CORT-induced LTP inhibition. The mPTP inhibitor TRO-19622 (25 M) prevented both the CORT-mediated activation of GSK-3␤ (one-way ANOVA, F(2,15) = 11.74, p = 0.003; Holm-Sidak post hoc test for CORT + TRO-19622 (94.9 ± 6.9%, p = 0.010) vs CORT (69.7 ± 3.6%), Fig. 2a ) and the inhibition of LTP (CORT: 114.3 ± 5.8%; CORT + TRO-19622: 144.1 ± 2.2%, unpaired t-test t(11) = 6.5, p = 0.001, Fig. 2b ). These results imply that aberrant regulation of mPTP activates caspase and GSK-3, which subsequently dysregulate LTP. Since caspase-3 can regulate GSK-3 through cleavage of Akt1 [18, 19] , we hypothesised that the observed caspase mediated upregulation of GSK-3 activity might be due to Akt1 cleavage and that this is a key sequential step in the inhibition of LTP. Previous findings have shown that phosphorylation of Akt1 modulates its cleavage in a site-specific manner [28] . We therefore measured the phosphorylation of Akt1 at Thr308, a site correlated with Akt1 cleavage and activity [29] . We found that Thr308 phosphorylation was significantly reduced by CORT treatment (one-way ANOVA, F(3,20) = 10.13, p < 0.001; Holm-Sidak post hoc test for CORT (42.2 ± 12.3%, p = 0.024) vs control (100.0 ± 13.0%), Fig. 2c ) and that this reduction was prevented by pre-treating slices with either Z-DEVD-FMK or the GR antagonist RU486 (500 nM), (CORT vs CORT + Z-DEVD-FMK (142.6 ± 17.5%, p < 0.001), CORT vs CORT + RU486 (114.7 ± 8.9%, p = 0.005, Fig. 2c) ). The total expression of Akt1 was unaffected by CORT, Z-DEVD-FMK or RU486 (one-way ANOVA, F(3,20) = 0.59, p = 0.632, Fig. 2c ). This suggests that CORT inhibits Akt1 activity via caspase activation, and is a specific consequence of GR activation. To further validate the effect of CORT on Akt1 activity, we used an in vitro kinase assay utilising immunoprecipitated Akt1 from control and CORT treated hippocampal slices and a GSK-3 fusion protein as a substrate to determine the activity of immobilised Akt1. We found that CORT treatment reduced Akt1 activity as observed by a significant decrease in phosphorylated GSK␣␤ at serine residues 21 and 9 (pGSK␣␤ Ser21/9) levels compared to control (control: 100.0 ± 8.44%; CORT: 73.9 ± 3.67%, unpaired t-test t(4) = 7.1, p = 0.002, Fig. 2d ). We next aimed to determine whether caspase-3-mediated Akt1 cleavage is important for the inhibition of LTP by CORT. To do this, we biolistically transfected mutant Akt1 protein (Akt1 triple mutant, resistant to cleavage by caspase-3 [18] ) into CA1 hippocampal neurons. CORT treatment did not impair LTP in cells transfected with the Akt1 triple mutant when compared to untransfected cells (untransfected: 104.9 ± 7.2%; Akt1 triple mutant transfected; 144.8 ± 13.5%, unpaired t-test t(9) = 2.5, p = 0.036, Fig. 2e ) but inhibited LTP in cells transfected with wild-type Akt1 (untransfected: 117.4 ± 11.7.%; Akt1 wild-type: 107.4 ± 16.3%, unpaired t-test t(10) = 0.5, p = 0.628, Fig. 2f ).
GCs induce pTau specifically at the PHF-1 epitope
Together, these results suggest that CORT-mediated LTP inhibition relies upon the cleavage of Akt1 by caspase-3 and this might be a critical step to further downstream signal cascades which ultimately execute functional synapse weakening. What remains to be shown, however, are the potential downstream substrates that mediate synaptic weakening and dysregulate LTP. GSK-3 is a well-characterised kinase of the tau protein, governing the phosphorylation of tau (pTau) at multiple sites [30] . Interestingly, pTau at Ser396, one of the GSK-3 target sites closely associated with pathogenesis in AD [30] , was recently revealed as necessary for LTD [21] . Given previous evidence showing increased pTau following stress [31] , we postulated that CORT-induced activation of GSK-3, via upstream caspase-3-Akt1 regulation, might culminate in greater pTau and thus aberrant modulation of synaptic plasticity. Therefore, we tested whether caspase, mPTP and GSK-3 activation are involved in CORTmediated changes to pTau. CORT treatment significantly increased immunoreactivity with the PHF-1 antibody, which detects pTau at amino acids Ser396 and Ser404 (S396/404) (one-way ANOVA, F(3,20) = 4.83, p < 0.001); Holm-Sidak post hoc test for control (100.0 ± 16.0%) vs CORT (135.9 ± 7.9%, p = 0.001, Fig. 3a) , and this effect of CORT occurred in a caspase dependent manner (CORT vs CORT + Z-DEVD-FMK (90.4 ± 4.4%, p < 0.001, Fig. 3a) ). We also tested AT8, an antibody that detects alternate GSK-3 phosphorylation residues Ser-202 and Thr-205, and found no change in phosphorylation at these sites (one-way ANOVA, F(3,20) = 0.43, p = 0.734, Fig. 3b) . The CORT-mediated increase in PHF-1 immunoreactivity was also prevented by co-treatment with an inhibitor of the mPTP ((one-way ANOVA, F(2,15) = 9.96, p < 0.001; Holm-Sidak post hoc test for control (100.0 ± 4.2%) vs CORT (139.7 ± 5.9%, p = 0.003), CORT vs CORT + TRO-19622 (88.2 ± 10.0%, p < 0.001, Fig. 3c) ) or an inhibitor of GSK-3 (139.8 ± 8.0%) vs CORT + CT-99021 (104.1 ± 10.4%, p = 0.008, Fig. 3e ). AT8 immunoreactivity was again unchanged in both cases (one-way ANOVA, F(2,15) = 0.58, p = 0.573, Fig. 3D ; one-way ANOVA, F(2,24) = 0.38, p = 0.69, Fig. 3f ). These data show that CORT-triggered signalling cascades drive an increase in pTau, specifically at residues of the PHF-1 epitope.
CORT-induced inhibition of LTP is mediated by specific pTau at Ser396
Based on previous findings that pTau is required for LTD induction as well as A␤-mediated LTP inhibition [21, 22] , we were interested in determining whether CORT-induced LTP inhibition is due to aberrant synapse weakening mediated through pTau. To test this, endogenous tau was first knocked down by rat tau small hairpin-forming interference RNA (shRNA) in cultured hippocampal slices [21] , allowing us to determine whether tau itself is critical to CORT-mediated LTP inhibition. Indeed, robust LTP was induced in rat tau shRNA transfected neurons, but not in untransfected neurons, that were treated with CORT (untransfected: 105.6 ± 17.9%; tau shRNA transfected: 162.9 ± 19.5%, unpaired ttest t(12) = 2.4, p = 0.032, Fig. 4a ). In addition, neurons where endogenous tau was replaced with S396/404 residue phospho-null human tau (S396/404A) readily exhibited LTP following treatment with CORT when compared to untransfected cells (untransfected: 100.1 ± 12.1%, S396/404A transfected: 145.5 ± 12.1%, unpaired ttest t(11) = 2.2, p = 0.040, Fig. 4b ), indicating that tau and its phosphorylation are important for the effect of CORT on LTP. We next wanted to determine whether there was a selective requirement for phosphorylation at either of these sites within this mechanism. We therefore generated and transfected neurons with single phospho-null tau mutants in conjunction with rat tau shRNA. We found that, following CORT treatment, LTP was present in neurons expressing the S396A mutant (untransfected: 84.0 ± 9.9%; S396A transfected: 177.0 ± 30.4%, unpaired t-test t(11) = 2.7, p = 0.020, Fig. 4c ) but not in neurons expressing the S404A form (untransfected: 101.9 ± 14.2%; S404A transfected: 108.8 ± 17.6%, unpaired t-test t(8) = 0.3, p = 0.770, Fig. 4d ). In contrast, neurons where endogenous tau was replaced with Ser199/202/Thr205 residue phospho-null human tau (S/T199/202/205A) were still sensitive to CORT-mediated inhibition of LTP (untransfected: 85.4 ± 13.0%; S/T199/202/205A transfected: 117.4 ± 11.7%, unpaired t-test t(9) = 1.8, p = 0.100, Middle: Quantification of pAkt1(Thr308) immunoreactivity normalised to total Akt1. Right: Total Akt1 normalised to ␤-actin loading control. The reduction in Thr308 phosphorylation of Akt1 following CORT treatment (n = 6) was rescued by Z-DEVD-FMK (n = 6) and RU486 (n = 6). (d) CORT treatment reduces Akt1 activity as determined by a significant decrease in pGSK␣␤ Ser21/9 levels compared to control (n = 3). (e and f) Whole cell patch clamp recording in CA1 region of cultured hippocampal slices. Top: Example traces of EPSCs from indicated timepoints. Bottom: Mean peak EPSC shown as percentage of the established baseline. (e) CORT does not impair LTP in slices transfected with Akt1 triple mutant (Akt1 triple mutant transfected n = 6, untransfected n = 5), (f) whereas Akt1 wild-type has no effect on CORT-induced LTP impairment (Akt1 wild-type n = 7, untransfected n = 6). 2 Hz stimulation indicated by black rectangles. All bars and circles represent the mean ± SEM. Statistical significance was determined by one-way ANOVA and Holm-Sidak post hoc analysis and unpaired t-test indicated as *p < 0.05, **p < 0.01, ***p < 0.001. Fig. 4e ). Together, these data suggest that pTau at the Ser396 residue is specifically required for CORT-induced inhibition of LTP.
Discussion
Our data are consistent with a serial synaptic weakening mechanism in which the activation of caspase-3 leads to cleavage of Akt1, removing the tonic inhibition of GSK-3, which subsequently increases pTau and causes inhibition of LTP. Caspase-3, GSK-3 and pTau are all critically involved in LTD, and aberrant LTD expression by these molecules has been implicated in the pathophysiology of synapse weakening and neurodegeneration [18, 19, 21, [32] [33] [34] [35] . Interestingly, LTP induction can inhibit LTD signalling cascades [17] and, conversely, aberrant activation of LTD and/or synapse weakening signalling cascades inhibits LTP expression [18, 19] . This suggests that LTP and LTD signalling molecules are tightly regulated and are maintained in balance at basal states. A given stimuli (i.e., GCs), therefore, could tip this balance in favor of LTP or LTD by acting as a catalyst for signalling mechanisms associated with one or the other form of plasticity. Previous studies have demonstrated that the inhibition of aberrantly expressed LTD and synapse weakening signalling molecules restores LTP expression ordinarily inhibited in an A␤ neurotoxicity model [19, 35] . Therefore, a compelling explanation for the data presented in this study is that GC-activated synapse weakening signalling results in the inhibition of LTP. Given the numerous studies showing GC-facilitated LTD [11, 12, 14] , there was significant scope for GCs activating key LTD/synapse weakening molecules. Among many of the LTD/synapse weakening molecules, we were specifically interested in GSK-3, considered pivotal in LTD expression and known to be involved in certain types of neurodegeneration [17, 36] . Underlying our focus on GSK-3 were the previous observations broadly linking GCs with upregulated GSK-3 activity [31, 37] , findings which are consistent with the results presented here. A next important step will be to determine the mechanisms by which GCs can modulate GSK-3 activity. GCs activate caspase-3 in cultured rat hippocampal neurons [38] and activation of GR specifically is known to regulate this proapoptotic pathway [39] . Indeed, our TRO-19622 experiment data suggest that GCs regulate the proapoptotic mPTP and cytochrome c, and this may serve as a key step in the activation of GSK-3. We have previously suggested that caspase-3-mediated cleavage of Akt-1 is critical for the activation of GSK-3 by A␤ and aberrant expression of LTD in the hippocampus [18] . Furthermore, the constitutive inhibition of GSK-3 is primarily governed by the PI3K-Akt signaling pathway [40] , which is subject to GC regulation [15, 16] . It has also been suggested that GCs inhibit the canonical wingless (WNT) pathway through Dickkopf 1 (DKK1) [41] , which can regulate GSK-3 activity [42] . Therefore, it is clear that signalling pathways converging on GSK-3 are indeed liable to modulation by GCs, and such events could serve as the means by which synapse weakening is induced by GCs.
In the view of activation of GSK-3 by GCs, we hypothesised that the downstream signalling of GSK-3 would promote LTD and/or synapse weakening molecules. Given that GSK-3 is a typical tau kinase and our previous study suggested that tau is essential for LTD expression [20] , this hypothesis was tested by knockdown of tau. As we recently found that tau phosphorylation by GSK-3 is a critical molecular step in LTD induction but has no role in LTP [21] , we also showed that a specific phospho-null mutation of tau blocked GC-mediated inhibition of LTP. Growing evidence now links GC exposure with tau phosphorylation [31, 38, [43] [44] [45] [46] , though the significance of this had remained relatively under explored. Our study now strongly suggests that GC-mediated GSK-3 activation regulates aberrant tau phosphorylation and this causes inhibition of LTP. The real consequences of this could then be twofold; firstly, the dysregulation of synaptic function as a result of the synapse weakening pathway activation. Secondly, GC-induced tau phosphorylation per se could seed tauopathies. It remains to be determined, however, whether there is a specific role of membrane-bound-GRs or cytosolic GRs in activating these signalling pathways that mediate the inhibition of LTP by CORT.
Of particular interest is our novel observation that specific phosphorylation of tau at Ser396 is central to GC-induced synapse weakening. Aside from the established role of this phosphorylation signal with physiological LTD [20, 21] , it is intriguing to note other studies linking the phosphorylation of tau at this residue with pathological conditions. In particular, GCs have been shown to induce the accumulation of tau specifically phosphorylated at Ser396 within the synaptic compartment [47] . Furthermore, tau phosphorylated at Ser396 is accumulated in the synaptic compartment of Alzheimer's disease and ␣-synucleinopathy brains and is considered to be one of the earliest cellular events associated with these pathologies [48, 49] . Therefore, the GC-activated caspase-3-GSK-3-pTau signalling pathway may be a potential molecular mechanism of stress mediated synapse weakening that primes neurodegenerative and precedes cognitive decline onset. Control of such aberrant synapse weakening signals may therefore be a useful symptom modification strategy for improvement of cognitive impairments, such as in dementia.
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